Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 14Other solid neoplasm 13Tumor-Agnostic 11Genitourinary 11Gastrointestinal 11Breast 11Lymphoid 7Dermatologic 6Sarcoma 5Other hematologic neoplasm 5CNS 4Head & Neck 2Plasma cell 1Other 1Gynecologic 1Endocrine 1

Conditions

Neoplasms, Plasma Cell 1Multiple Myeloma 1

Interventions

Dexamethasone 882Bortezomib 481Lenalidomide 467Cyclophosphamide 367Melphalan 276Calcium Dobesilate 265daratumumab 241pomalidomide 216carfilzomib 188fludarabine phosphate 141fludarabine 137Thalidomide 125Peripheral Blood Stem Cell Transplantation 120Filgrastim 115ixazomib 94Mycophenolic Acid 91Granulocyte Colony-Stimulating Factor 90Busulfan 89Whole-Body Irradiation 88dexamethasone acetate 87Tacrolimus 79dexamethasone 21-phosphate 74isatuximab 70Cyclosporine 68auricularum 67Prednisone 67elotuzumab 63belantamab mafodotin 60Antilymphocyte Serum 56Etoposide 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Midazolam × Plasma cell × Clear all
NCT01456689 2020-12-17

A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma

Novartis

Phase 1 Completed
79 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡